Dr. Tseng is a physician-scientist and received MD from National Taiwan University Medical School in 1978, and Ph.D. from University of California San Francisco in 1981. He completed the ophthalmology residency at Johns Hopkins Hospital (1984) and the cornea and external disease fellowship at Massachusetts Eye & Ear Infirmary, Harvard Medical School (1986). He was Charlotte Breyer Rodgers chair professor at Bascom Palmer Eye Institute University of Miami School of Medicine (till 2002). He served as the first President of the International Ocular Surface Society (2000 to 2004). He received Senior Achievement Award (2004), Secretariat Award (2005), and Life Achievement Honor Award (2016) from the American Academy of Ophthalmology, and is an ARVO Gold Fellow. He serves as an ad hoc member of several NIH study sections, and the editorial board of Ocular Surface Journal, Cornea Journal, and Translational Vision Science and Technology. Dr. Tseng is specialized in ocular surface diseases and reconstruction using new surgical techniques of epithelial stem cell transplantation and amniotic membrane transplantation. His research focuses on epithelial stem cell biology, tissue engineering, and the platform technology based on his discovery of a novel amniotic membrane/umbilical cord regenerative matrix, and has been continuously supported by NIH, National Eye Institute for over 30 years. He combines his expertise in clinical services, education and research, and has produced more than 360 peer-reviewed papers and trained more than 80 international fellows specialized in ocular surface diseases. Presently, He is the medical director of Ocular Surface Center and Ocular Surface Research & Education Foundation, and the Chief Technology Officer of TissueTech, Inc., which together with its two subsidiaries, i.e., Bio-Tissue, Inc. and Amniox Medical, Inc., is the leading tissue engineering and biologic company, in Ophthalmology, Foot and Ankle and Skin.